The Branded Health Service Medicines (Costs) (Amendment) Regulations 2026
These Regulations amend the Branded Health Service Medicines (Costs) Regulations 2018 (S.I. 2018/345) (the “Statutory Scheme Regulations”). The Statutory Scheme Regulations, amongst other matters, make a scheme for the purpose of requiring specific manufacturers and suppliers of branded medicines for health service use to pay certain amounts to the Secretary of State. These amounts are calculated by reference to the net sales income or estimated net sales income from supplies of such medicines. These amendments update the payment percentages for 2026 and subsequent years.
Lifecycle
Department
Made
09 Jun 2026
—
Comes into force
01 Jul 2026
Enabling power
The Secretary of State for Health and Social Care makes the following Regulations in exercise of the powers conferred by sections 263(1)(b) and (c), (2) and (5), 264(3), 266(1) and 272(7)(a) and (b) and (8) of the National Health Service Act 2006 having had regard to the matters specified in section 266(3), (4) and (4A) of that Act. The Secretary of State has consulted in accordance with sections 263(1) and (1A) of that Act.
DocumentsOpen on legislation.gov.uk →